FDA Medical Device Recalls Decoded: 58K Records, Root Causes, and Trends

Executive Summary

FDA medical device recalls are among the most consequential post-market actions a manufacturer can face — they signal a failure somewhere in the design, production, or distribution chain that reached patients. But how common are recalls, what drives them, and which companies and device types are most affected?

Our analysis of the complete FDA medical device recall database — 58,374 recall events from 2002 through June 2026, involving over 5,500 unique firms and spanning every device specialty — quantifies the scale and patterns of US device recalls. Cross-referencing with the FDA enforcement report database (40,274 classified recall events) shows that 85.8% of classified recalls are Class II (moderate risk), 10.7% are Class I (life-threatening), and 3.5% are Class III (low risk).

Device design is the single largest identified root cause at 13.0%, followed by process control failures (11.0%) and nonconforming materials (9.9%). Together with software design (5.9%) and packaging issues (6.0%), these five categories account for nearly half of all recalls where a cause is documented.

Boston Scientific leads all firms with 1,044 recall events (1.8% of the total), but the market is highly fragmented — the top 25 firms account for only 26.8% of all recalls. Intravenous administration sets (product code FPA) are the single most recalled device type at 1,080 events.

This article breaks down the classification mix, root causes, responsible firms, device types, and year-over-year trends to help regulatory and quality professionals benchmark their own recall exposure.

Data Source and Methodology

All statistics in this article are derived from our direct analysis of two FDA public databases:

1. FDA device recall database (openFDA, extracted June 2026): 58,374 recall event records containing the recalling firm, product code, product description, root cause description, reason for recall, event date initiated, and recall status. This dataset spans October 2002 through June 2026.

2. FDA device enforcement report database (openFDA, extracted June 2026): 40,274 enforcement records containing the recall classification (Class I, II, or III), recalling firm, product code, and report date. This dataset is a subset of recalls that have been formally classified by FDA.

Root cause categories are taken directly from the FDA-assigned root cause description field. Additional reason-for-recall text was sampled (5,000 records) and categorized by keyword analysis to identify thematic patterns. Product codes were resolved to device names and medical specialty panels using the FDA product classification database. Percentages are calculated against the relevant denominator (total records unless otherwise noted).

Recall Classification: The Class II Dominance

FDA classifies recalls into three tiers based on the probability and severity of harm:

Source: FDA enforcement report database (40,274 classified records). Unclassified counts are the difference between the 58,374 recall events and 40,274 classified events.

The overwhelming Class II share (85.8%) reflects the nature of most device recalls — they address issues that could cause harm but are unlikely to be life-threatening. Typical Class II scenarios include labeling discrepancies, packaging integrity concerns, and minor performance deviations.

The 4,316 Class I recalls (10.7%) represent the highest-risk events. These include situations where device failure has directly caused or could cause death or serious injury — software malfunctions in life-support equipment, sterility failures in implantable devices, or mechanical failures in critical therapeutic devices.

Root Causes: What Drives Recalls

The FDA assigns a root cause description to each recall event. Across the full 58,374-record dataset, the distribution is:

Several patterns deserve attention:

• Device design is the leading identified cause. At 13.0%, design-related issues (including Device Design at 13.0% and Component Design at 2.7%) account for the largest share of root causes where the FDA has made a determination. This underscores the importance of robust design controls and design verification/validation before market entry.

• Manufacturing process failures are systemic. Process Control (11.0%), Packaging Process Control (2.5%), Process Design (2.0%), and Process Change Control (1.5%) together represent 17.0% of recalls — pointing to gaps in production controls, change management, and CAPA effectiveness.

• Software is a growing concern. At 5.9%, software design is the sixth most common root cause. As devices become more software-dependent, this category is likely to grow.

• Material quality matters. Nonconforming Material/Component (9.9%) and Material/Component Contamination (1.2%) together account for 11.1% — highlighting the importance of supplier management and incoming material controls.

• "Under Investigation" is common. At 11.5%, a substantial share of recalls have not yet had their root cause formally determined by the recalling firm. This reflects the time lag between recall initiation and root cause investigation completion.

Reason-for-Recall Text Patterns

Beyond the structured root cause field, the free-text reason for recall reveals additional patterns. A keyword analysis of 5,000 sampled records shows:

Sterility assurance is the single most common explicit reason — failures range from compromised packaging seals to confirmed microbial contamination. For implantable and surgical devices, sterility recalls are often Class I because of the direct infection risk to patients.

Which Companies Recall the Most

The recall database spans over 5,500 unique firms, but the distribution is heavily concentrated at the top:

Concentration metrics:

• Top 5 firms: 4,428 events (7.6% of all recalls)

• Top 10 firms: 7,288 events (12.5%)

• Top 25 firms: 15,657 events (26.8%)

• Remaining 5,500+ firms: 42,717 events (73.2%)

Several observations:

• Portfolio size drives recall volume. Boston Scientific, Zimmer Biomet, and Siemens each market thousands of device models. A firm with a large installed base and broad product line is statistically more likely to experience recalls. High recall counts do not necessarily indicate poor quality — they often reflect the scale of the product portfolio and the rigor of the firm's voluntary recall reporting.

• Orthopedics and imaging are overrepresented. Zimmer, Biomet, DePuy, and Stryker are all major orthopedic manufacturers — together accounting for thousands of events. Siemens and GE dominate imaging-related recalls.

• Medline and Customed reflect high-volume disposables. Medline (812) and Customed (699) are large distributors of disposable medical products (admin sets, surgical trays, gloves). Their high recall counts reflect the sheer volume of SKUs they manage rather than systemic quality issues.

• Legacy brands appear multiple times. Zimmer Inc. and Zimmer Biomet Inc. are listed separately due to mergers and name changes. Similarly, Siemens Medical Solutions and Siemens Healthcare Diagnostics are separate entries. Aggregating across brand families would push some firms higher.

Most Recalled Device Types

The top 25 product codes by recall frequency reveal which device categories are most affected:

By medical specialty panel (aggregated across all product codes):

The product code rankings highlight several risk patterns:

• IV administration sets (FPA) lead all product codes at 1,080 events. These are high-volume, single-use devices where recalls are often driven by particulate matter, sterility concerns, or tubing integrity issues.

• Surgical trays (LRO) rank second at 1,020 events. Assembled kits containing multiple components are inherently more prone to recall because any single component failure triggers a kit-level recall.

• Orthopedic implants dominate the top ranks. Knee prostheses (JWH, 980), intramedullary rods (HSB, 689), and bone screws (HWC, 387) together represent a substantial share — reflecting both the high volume of orthopedic procedures and the criticality of implant performance.

• Imaging equipment has high event counts. CT systems (JAK, 857), MRI systems (LNH, 699), fluoroscopy systems (OWB, 610), and linear accelerators (IYE, 559) all rank in the top 15. These are complex, software-driven systems where recalls often address software defects, calibration issues, or safety interlock failures.

Year-Over-Year Trend: Rising Recall Volume

The annual recall count has trended upward over the past two decades:

Key observations:

• Peak year was 2017 at 3,313 recalls, driven in part by a surge in recalls related to sterile packaging, infusion pump software, and imaging equipment service bulletins.

• A dip occurred in 2020–2022 (2,602 to 2,276), coinciding with the COVID-19 pandemic. This likely reflects a combination of factors: FDA regulatory flexibility during the public health emergency, reduced elective procedures (and therefore reduced device usage and adverse event reporting), and disrupted supply chains that may have slowed recall initiation.

• Volume rebounded in 2023–2024, reaching 3,275 in 2024 — the second-highest year on record and within striking distance of the 2017 peak.

• 2025 saw 2,831 events, a slight decline from 2024 but still above pre-pandemic levels. Industry reports note that Class I recalls specifically reached a 15-year high in 2024, with Q1 2025 recording 31 Class I events — the second-highest quarterly total in two decades.

• 2026 is on pace for approximately 2,800–3,000 events based on the first half (947 through June), consistent with the elevated post-pandemic baseline.

Recall Status: Most Are Terminated

The current status of the 58,374 recall events:

The overwhelming majority (76.4%) have been terminated, meaning the FDA has determined that the recall has been adequately completed. The 22.9% "Open, Classified" figure represents active recalls still in progress. The very small "Completed" category (0.8%) reflects a status used less frequently in the database.

What This Means for Industry

Several takeaways emerge from the data:

1. Design controls remain the highest-leverage intervention. Device design is the leading identified root cause (13.0%). Investing in design verification, usability testing, and risk analysis before market entry remains the most effective way to reduce recall risk.

2. Manufacturing process discipline is critical. Process control (11.0%), process design (2.0%), and change control (1.5%) together represent a substantial share of recalls. Robust process validation, change management, and CAPA systems are essential.

3. Sterility assurance demands constant vigilance. Sterility-related recalls (8.1% of sampled reasons) are disproportionately likely to be Class I due to the infection risk. Manufacturers of sterile devices should treat packaging validation and environmental monitoring as critical quality functions.

4. Software recalls are growing. At 5.9% of root causes, software design is already a significant factor and likely undercounted — many "Device Design" and "Other" root causes may have software components. As medical devices become more software-intensive, this category will grow.

5. Supplier management is a strategic priority. Nonconforming materials (9.9%) and component issues (2.7%) together account for 12.6% of recalls. Manufacturers should implement rigorous supplier qualification, incoming inspection, and supply chain monitoring.

6. Large portfolios carry large recall exposure. Firms with thousands of active SKUs (Boston Scientific, Siemens, Zimmer Biomet) will inevitably experience more recall events. The key metric is not total recall count but recall rate relative to active product count and units distributed.

7. AI/ML-enabled devices face outsized recall risk. A recent analysis of FDA recall data for AI/ML-enabled medical devices found that software design accounts for 42% of AI/ML device recalls — approximately seven times the rate for all 510(k) devices combined (~6%). As AI-driven diagnostics and therapeutic devices proliferate, manufacturers should anticipate heightened regulatory scrutiny of software validation and change control.

Data source: FDA medical device recall database and enforcement report database (openFDA), extracted June 2026. Analysis by MedDeviceGuide. All statistics are derived from direct computation on the public dataset. Recall classification counts are from the enforcement report database (40,274 classified records); root cause, firm, product code, and year data are from the full recall event database (58,374 records).